Avacta Group Plc - notizie pubblicate 142 - letture 4.965
AVACTA GROUP PLC
ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data
The data confirm the pre|cisiontm platform's ability to transform the safety profile of doxorubicin through tumour targeting cohort 7, the final cohort in the three-weekly dose esc ...
AVACTA GROUP PLC
Targeting the Tumour Microenvironment: Redefined – AVA6000 Update December 2023
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Shareholder update to review AVA6000 Phase 1a data
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, will hold an online shareholder event via the investo ...
AVACTA GROUP PLC
Issue of Equity and Total Voting Rights
Avacta group plc (aim: avct), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics today announces it has issued and ...
AVACTA GROUP PLC
Block Listing Application to AIM
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Block Listing Application to AIM
Avacta group plc (aim: avct), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, announces application has been ma ...
AVACTA GROUP PLC
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Ava3996: fap-α-activated proteasome inhibitor from pre|cisiontm platform concentrates proteasome inhibitor payload in the tumour, increasing the therapeutic index of this class of ...
AVACTA GROUP PLC
Director/PDMR Shareholding
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Director/PDMR Shareholdings
Avacta group plc (aim: avct), a life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics, announces it has granted a total ...
AVACTA GROUP PLC
Interim Results for the Period Ending 30 June 2023
A period of substantial clinical progress and continued growth avacta group plc (aim: avct), a life sciences company focused on improving healthcare outcomes through targeted cance ...
AVACTA GROUP PLC
Interim Results for the Period Ending 30 June 2023 – presentation slides
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Interim Results for the Period Ending 30 June 2023
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Issue of Equity and Total Voting Rights
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces it has received a notice of conversio ...
AVACTA GROUP PLC
Issue of Equity and Total Voting Rights
The text version of this document is not available. you can access the original document here. attachments original link original document permalink disclaimer avacta group plc pub ...
AVACTA GROUP PLC
Peel Hunt Appointed as Joint Broker
Avacta group plc (aim: avct), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that it has appointed peel hunt llp ( ...
Per i consulenti finanziari
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti